secwatch.observer — SEC 8-K summary
======================================

Issuer:     Monte Rosa Therapeutics, Inc. (GLUE)
CIK:        0001826457
Form:       8-K
Filed at:   2022-08-11T23:59:59+00:00
Accession:  0000950170-22-016647
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Monte Rosa Q2 2022 net loss $26.5M; IND submitted for MRT-2359
--------------------------------------------------------------

- Net loss of $26.5M for Q2 2022, compared to $18.4M in Q2 2021.
- Cash, equivalents, and marketable securities of $299.5M as of June 30, 2022; expected runway into late 2024.
- R&D expenses of $20.9M in Q2 2022 vs $14.6M in Q2 2021, driven by MRT-2359 advancement and platform expansion.
- Submitted IND for MRT-2359 (GSPT1 degrader) for Myc-driven solid tumors; Phase 1/2 trial planned for Q4 2022.
- Progress on CDK2 and NEK7 programs toward development candidate nominations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1826457/000095017022016647/0000950170-22-016647-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1826457/000095017022016647/glue-20220811.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-016647

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer